title: Structure-activity relationship of nerve-highlighting fluorophores.
abstract: Nerve damage is a major morbidity associated with numerous surgical interventions. Yet, nerve visualization continues to challenge even the most experienced surgeons. A nerve-specific fluorescent contrast agent, especially one with near-infrared (NIR) absorption and emission, would be of immediate benefit to patients and surgeons. Currently, there are only three classes of small molecule organic fluorophores that penetrate the blood nerve barrier and bind to nerve tissue when administered systemically. Of these three classes, the distyrylbenzenes (DSBs) are particularly attractive for further study. Although not presently in the NIR range, DSB fluorophores highlight all nerve tissue in mice, rats, and pigs after intravenous administration. The purpose of the current study was to define the pharmacophore responsible for nerve-specific uptake and retention, which would enable future molecules to be optimized for NIR optical properties. Structural analogs of the DSB class of small molecules were synthesized using combinatorial solid phase synthesis and commercially available building blocks, which yielded more than 200 unique DSB fluorophores. The nerve-specific properties of all DSB analogs were quantified using an ex vivo nerve-specific fluorescence assay on pig and human sciatic nerve. Results were used to perform quantitative structure-activity relationship (QSAR) modeling and to define the nerve-specific pharmacophore. All DSB analogs with positive ex vivo fluorescence were tested for in vivo nerve specificity in mice to assess the effect of biodistribution and clearance on nerve fluorescence signal. Two new DSB fluorophores with the highest nerve to muscle ratio were tested in pigs to confirm scalability.
authors.affiliation: Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.
authors.forename: Summer L
authors.initials: SL
authors.lastname: Gibbs
authors.forename: Yang
authors.initials: Y
authors.lastname: Xie
authors.forename: Haley L
authors.initials: HL
authors.lastname: Goodwill
authors.forename: Khaled A
authors.initials: KA
authors.lastname: Nasr
authors.forename: Yoshitomo
authors.initials: Y
authors.lastname: Ashitate
authors.forename: Victoria J
authors.initials: VJ
authors.lastname: Madigan
authors.forename: Tiberiu M
authors.initials: TM
authors.lastname: Siclovan
authors.forename: Maria
authors.initials: M
authors.lastname: Zavodszky
authors.forename: Cristina A
authors.initials: CA
authors.lastname: Tan Hehir
authors.forename: John V
authors.initials: JV
authors.lastname: Frangioni
mesh_terms: D000328:Adult; D000818:Animals; D003287:Contrast Media / Q000737:chemistry / Q000378:metabolism* / Q000493:pharmacokinetics; D005260:Female; D005456:Fluorescent Dyes / Q000737:chemistry / Q000378:metabolism* / Q000493:pharmacokinetics; D006801:Humans; D051379:Mice; D061848:Optical Imaging / Q000379:methods*; D051381:Rats; D012584:Sciatic Nerve / Q000737:chemistry / Q000378:metabolism*; D013050:Spectrometry, Fluorescence; D019265:Spectroscopy, Near-Infrared; D013329:Structure-Activity Relationship; D013343:Styrenes / Q000737:chemistry / Q000378:metabolism* / Q000493:pharmacokinetics; D013552:Swine; D014018:Tissue Distribution
chemical_list: D003287:Contrast Media; D005456:Fluorescent Dyes; D013343:Styrenes; C507243:distyrylbenzene
references.citation: Mol Imaging Biol. 2012 Dec;14(6):708-17
references.pmid: 22488576
references.citation: J Med Chem. 2008 Nov 13;51(21):6682-8
references.pmid: 18844339
references.citation: Brain Res. 1999 Aug 7;837(1-2):289-97
references.pmid: 10434014
references.citation: World J Urol. 2007 Mar;25(1):31-8
references.pmid: 17333199
references.citation: Nat Chem Biol. 2007 Aug;3(8):438-41
references.pmid: 17637769
references.citation: J Histochem Cytochem. 2005 Dec;53(12):1511-6
references.pmid: 16046669
references.citation: J Neurosci. 2003 May 15;23(10):4054-65
references.pmid: 12764092
references.citation: Mol Imaging. 2011 Apr;10(2):91-101
references.pmid: 21439254
references.citation: Mol Imaging. 2010 Jun;9(3):128-40
references.pmid: 20487679
references.citation: Mol Imaging. 2009 May-Jun;8(3):156-65
references.pmid: 19723473
references.citation: Technol Cancer Res Treat. 2003 Dec;2(6):553-62
references.pmid: 14640766
references.citation: Molecules. 2008 Jun 20;13(6):1406-26
references.pmid: 18596666
references.citation: Br J Anaesth. 2008 Jul;101(1):77-86
references.pmid: 18434337
references.citation: Nat Biotechnol. 2011 Apr;29(4):352-6
references.pmid: 21297616
references.citation: CA Cancer J Clin. 2008 Jul-Aug;58(4):196-213
references.pmid: 18502900
references.citation: Mol Imaging. 2002 Oct;1(4):365-77
references.pmid: 12940233
references.citation: J Histochem Cytochem. 2006 Sep;54(9):997-1004
references.pmid: 16709728
references.citation: Eur J Surg Oncol. 2011 Jan;37(1):32-9
references.pmid: 21106329
references.citation: Mol Imaging Biol. 2011 Apr;13(2):199-207
references.pmid: 20617389
references.citation: Nat Biotechnol. 2008 Dec;26(12):1367-72
references.pmid: 19029910
references.citation: Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
references.pmid: 11259830
references.citation: Stain Technol. 1957 Jan;32(1):19-23
references.pmid: 13391323
references.citation: Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9304-9
references.pmid: 16754874
references.citation: Ann Surg Oncol. 2006 Dec;13(12):1671-81
references.pmid: 17009138
references.citation: J Med Chem. 1997 Dec 5;40(25):4026-9
references.pmid: 9406594
references.citation: J Neuropathol Exp Neurol. 1953 Oct;12(4):400-3
references.pmid: 13097193
references.citation: Annu Rev Med. 2010;61:359-73
references.pmid: 20059343